ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1

NCT07472322 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

31

Enrollment

OTHER

Sponsor class

Conditions

Merkel Cell Carcinoma
Merkel Cell Carcinoma, Stage III
Merkel Cell Carcinoma, Stage IV

Interventions

DRUG: ASTX727 + retifanlimab

Sponsor

University of Wisconsin, Madison